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a  b  s  t  r  a  c  t
Vaccination  is  the most  effective  means  of preventing  inﬂuenza.  However,  the  cost  of  producing  annual
seasonal  inﬂuenza  vaccines  puts  them  out of  reach  for most  developing  countries.  While  live  attenuated
inﬂuenza  vaccines  are  among  the  most  efﬁcacious  and  can be manufactured  at low  cost,  they  may  require
lyophilization  to  be stable  enough  for developing-country  use, which  adds  a signiﬁcant  cost  burden.  The
development  of  a liquid  live  attenuated  seasonal  inﬂuenza  vaccine  that  is stable  for  around  a year—the
duration  of an  annual  inﬂuenza  season—would  signiﬁcantly  improve  not  only  the  production  output  but
also  the use  and  accessibility  of  inﬂuenza  vaccines  in  low-resource  settings.
In  this  study,  potential  stabilizing  excipients  were  screened  and  optimized  using  the  least stable
inﬂuenza  vaccine  strain  presently  known,  H1N1  (A/California/07/2009),  as a model.  The stability-
conferring  properties  of the  lead  formulations  were  also  tested  with  a  Type  B  strain  of inﬂuenza  virus
(B/Brisbane/60/2008).  Stability  was  also  evaluated  with  higher  titers  of inﬂuenza  virus  and  exposure  to
agitation  and  freeze–thaw  stresses  to  further  conﬁrm  the stability  of  the lead  formulations.  Through
this  process,  we  identiﬁed  a liquid  formulation  consisting  of  sucrose  phosphate  glutamate  buffer  with
1% arginine  and  0.5% recombinant  human  serum  albumin  that  provided  storage  stability  of one  year  at
2–8 ◦C  for  the  inﬂuenza  A and  B strains  tested.
ublis©  2016  The  Authors.  P
. Introduction
Seasonal inﬂuenza affects millions of people each year, causing
orbidity, mortality, and economic loss [1]. Vaccination is essential
o prevent inﬂuenza virus infections [2] and is especially important
o prevent inﬂuenza pandemics [3].
Inﬂuenza strains are characterized by surface glycoproteins
nd are classiﬁed into three types: A, B, and C strains. Because
nly strains A and B cause respiratory disease, vaccines target
hese subtypes. Within each subtype, inﬂuenza viruses are fur-
her categorized based on antigenic determinants in their surface
lycoproteins hemagglutinin (HA) and neuraminidase (NA) [2,4].
Inﬂuenza viruses undergo constant antigenic drift and antigenic
hift. Point mutations in viral RNA during viral replication cause
ntigenic drift [4]. Antigenic shift occurs when two inﬂuenza strains
xchange genome segments in a process called reassortment,
esulting in a new virus [3]. Recommended inﬂuenza vaccines
hange each year due to frequent, rapid changes in antigenic
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determinants in circulating strains [5]. Immune responses gener-
ated by vaccination are directed against the HA and NA proteins
[4].
Two main types of vaccines are licensed to prevent seasonal
inﬂuenza. These are inactivated inﬂuenza vaccines (IIVs) and live
attenuated, cold-adapted inﬂuenza virus vaccines (LAIVs). IIVs are
licensed for intramuscular delivery to anyone six months of age or
older and exist as inactivated whole virus particles or as split virion
and recombinant subunit vaccines [2,6–10]. Although millions of
people have received split and subunit vaccines, these vaccines are
less effective in young children [6,9,11–14]. LAIVs are made by com-
bining the HA and NA genes of the target strain into an inﬂuenza
virus genome that has been attenuated by adaptation to growth in
colder temperatures [15–19]. Cold-adapted viruses are developed
by continual passage of wild-type inﬂuenza virus in primary chick
kidney cells [16,20,21]. LAIVs express the antigenic phenotype of
the target strain with the attenuated phenotype of the cold-adapted
backbone, greatly reducing replication at body temperatures [9,21].
Replication of LAIV in the upper respiratory tract confers mucosal
immunity and a circulating neutralizing antibody response.
Moreover, a cell-mediated immune response similar to infection
with wild inﬂuenza, may  offer broader protection against strain




























































copeia (USP) grade reagents or Generally Regarded as Safe (GRAS).
Formulations were prepared by diluting bulk vaccine into the for-
mulations at a 1:10 ratio to achieve a ﬁnal live virus titer of
2 × 106 log10 TCID50/mL  or where noted at a 1:5 ratio to achieve
Table 1
LAIV liquid formulations evaluated.
Formulation
number
Components Inﬂuenza strain tested
F1 SPG buffer H1N1 and type B
F2  SPG + 0.5% sorbitol H1N1
F3 SPG + 3% sorbitol H1N1
F4 SPG + 0.5% gelatin H1N1
F5 SPG + 3% gelatin H1N1
F6 SPG + 0.5% BSA H1N1
F7 SPG + 3% BSA H1N1
F8 SPG + 0.1% arginine H1N1
F9 SPG + 1% arginine H1N1 and type B
F10 SPG + 0.5% glycine H1N1
F11 SPG 100 mM potassium phosphate H1N1
F12 SPG + 3% arginine H1N1
F13 SPG + 1% HPMC H1N1
F14 SPG + 1% PVP H1N1
F15 SPG + 1% lactalbumin H1N1
F16 SPG + 1% arginine and 0.5% gelatin H1N1
F17 SPG + 1% arginine and 0.5% BSA H1N1
F18 SPG + 1% arginine and 9% BSA H1N1
F19 SPG + 1% arginine and 0.5% HSA H1N1 and type BJ.A. White et al. / Vac
ariants [9]. Flumist® (MedImmune Vaccines Inc., Gaithersburg,
aryland, United States), a licensed LAIV, is delivered intranasally
nd is approved for use in healthy, non-pregnant subjects 2–49
ears old [9,19,22,23]. Its advantages over IIVs include sim-
ler manufacturing, higher yield, faster release, and ease of use
22,24]. Although no clear correlates of immunity for LAIV are
eﬁned, immune protection has been associated with serum
emagglutination-inhibition antibody and secretory immunoglob-
lin A (IgA) [25]. Also, randomized control trials found that LAIVs
re more efﬁcacious than IIVs in children, making them attractive
or seasonal prevention efforts [25–30]. FluMist® contains the same
ntigens as the IIV for that season and has reported stability of 18
eeks at 2–8 ◦C [23]. LAIVs could be more widely used if they were
table at 2–8 ◦C for 1 year, or an entire inﬂuenza season.
To increase global vaccine supplies and support development
f inﬂuenza vaccines in developing countries, the World Health
rganization selected three developing-country manufacturers for
 technology transfer initiative to strengthen capacity to pro-
uce LAIV against seasonal and pandemic inﬂuenza. This support
ranted manufacturers access to strains necessary for producing
accines, especially the live-attenuated master donor virus strain
rom the Institute of Experimental Medicine (IEM; St. Petersburg,
ussia) [24,31]. Serum Institute of India Ltd. (SIIL) was  selected to
roduce monovalent LAIV and trivalent seasonal LAIV using the
EM vaccine donor virus backbone for inﬂuenza A and B viruses
24,32]. Although SIIL developed a commercial LAIV H1N1 vaccine,
o achieve a one-year shelf life at 2–8 ◦C, the lyophilized product is
ostly and requires multiple handling steps before administration,
imiting its programmatic suitability [22,33].
The development of a low-cost, liquid formulation that is stable
or an entire inﬂuenza season would contribute to greater accep-
ance by manufacturers and wider use of LAIV while decreasing
roduction and distribution costs by removing the need for
yophilization [22].
Liquid LAIV formulation development at PATH included four
teps: (1) screening potential excipients, (2) optimizing lead formu-
ations, (3) validating lead formulations with an alternate inﬂuenza
irus strain, and (4) conﬁrming formulation stability with a higher
iter of virus, agitation, and freeze–thaw exposure. This process
roduced a liquid LAIV formulation stable for 1 year at 2–8 ◦C.
. Materials and methods
.1. Virus potency assay
A tissue culture infectious dose50 (TCID50) procedure based on
ublished methods was adapted for use with a colorimetric dye to
etermine the viral titer of inﬂuenza vaccine formulations [34–36].
 Madin-Darby canine kidney (MDCK) cell line from Inﬂuenza
eagent Resource (IRR) was selected for use in this assay (IRR FR-58,
ot 58851661). In addition, the reagent PrestoBlue (Life Technolo-
ies A13262) was selected to determine cell viability after infection.
ells were plated in 96-well plates (Nunc 167314) by adding 0.2 mL
f 0.75 × 105 cells/mL to each well and incubated at 37 ◦C with
% CO2 for 18–24 h. Plated cells were washed and maintained in
erum-free Eagle’s minimum essential medium (ATCC) containing
0 mg/mL  tosyl-phenylalanyl-chlorophenyl ketone (TPCK)-treated
rypsin (cat# TRTVMF, Worthington Biochemical Corporation).
nﬂuenza virus was serially 10-fold diluted and MDCK cell mono-
ayers were infected with inﬂuenza virus at dilutions of 10−2 to
0−8, with a total of six replicates per dilution and 0.2 mL  inoculum
er well. Plates were incubated for 6 days at 33 ◦C with 5% CO2. After
iral replication, dye was added to detect cell viability. Assay perfor-
ance was monitored by including a sample of LAIV (NASOVAC®)
ith each assay. Lyophilized LAIV (NASOVAC®) supplied by SIIL (2016) 3676–3683 3677
was stored at −30 ◦C (to prevent any measureable loss in titer
during these studies) in single-use aliquots for an assay control.
Titers were determined using the Reed-Muench formula [36]. The
assay variability was ±0.23 log10 TCID50/mL. Live virus titers deter-
mined by the TCID50 assay were compared to those determined
with the 50% Egg Infectious Dose (EID50) assay (the SIIL potency
release assay) and found to be approximately 0.5 log10 lower. As
the detection limit of the TCID50 assay is 2 × 103 log10 TCID50/mL,
changes in titer of greater than 0.5 log10 loss are detectable by
this assay. LAIV formulation stability was  deﬁned as the time to
1 log10 loss of virus titer. Because this was a feasibility study,
a 1 log loss threshold was  selected, representing approximately
0.23 log10 TCID50/mL  (variability of the TCID50 assay) plus a true
loss of approximately 0.7 log10 TCID50/mL, giving approximately
1 log10 loss of initial virus titer.
2.2. Vaccine formulation
The starting materials, monovalent bulk inﬂuenza vaccines
H1N1 (A/California/07/2009) and type B (B/Brisbane/60/2008),
were provided by SIIL in sucrose phosphate glutamate (SPG)
buffer at a concentration of 2 × 107 log10 TCID50/mL. Formu-
lations were prepared as indicated in Table 1. Formulations
were monitored for pH, osmolality, and appearance by visual
inspection. All formulations were within a pH range of 6.7–7.2
and an osmolarity range of 309–522 mOsm.  The following
excipients were evaluated: sucrose (Macron, cat#7723-04), gluta-
mate (Sigma, cat#49621), sorbitol (Spectrum, cat#S0219), gelatin
(Sigma–Aldrich, cat#G0262), bovine serum albumin (BSA) (Roche,
cat#03117332001), arginine HCl (Sigma, cat#A4599), glycine (JT
Baker, cat#0581-01), potassium phosphate monobasic (Macron,
cat#7746-04), potassium phosphate dibasic (Sigma, cat#P3786),
lactalbumin (Spectrum, cat#L3065), hydroxypropyl methylcellu-
lose (HPMC) (Sigma, cat#423238), polyvinylpyrrolidone (PVP)
(BASF Kollidon 17PF), recombinant human serum albumin (rHSA)
(Novozymes), and human serum albumin (HSA) (MP  Biomedicals,
LLC, cat# 0882351). All excipients were United States Pharma-F20 SPG + 1% arginine and 0.5% rHSA H1N1 and type B
Abbreviations: SPG, sucrose phosphate glutamate; BSA, bovine serum albumin;
HPMC, hydroxypropyl methylcellulose; PVP, polyvinylpyrrolidone; HSA, human
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 ﬁnal live virus titer of 1 × 107 log10 TCID50/mL. All formulations
ere held in glass vials (West Pharmaceutical Services, Exton, PA)
ontaining 1 mL  for stability testing at 2–8 ◦C, 25 ◦C, and 33 ◦C. Loss
as determined by TCID50 assay. Initially, we performed acceler-
ted stability temperature testing at 37 ◦C, but most formulations
ost greater than 1 log10 within 3 days. We  selected a temperature
f 33 ◦C for stability testing to improve resolution of the decay rate.
ormulations were tested as indicated in each experiment or until 1
og10 loss was observed. Each experiment involved triplicate testing
f one vial of each formulation at each time point. Lead formulations
ere repeated in subsequent formulation experiments. Stability
uring agitation was evaluated by horizontally shaking vials con-
aining formulations for 24 h at 200 rpm at 20–25 ◦C. Freeze–thaw
as performed by freezing vials at −20 ◦C for 2 h and then thawing
t 20–25 ◦C for 1 h, for three cycles.
.3. Statistical analysis
The decay rate was determined using the slope of the stability
ata in a linear regression model (GraphPad Prism software version
). Data points at or below the limit of detection were excluded
rom the analysis. Statistically signiﬁcant differences in the stabil-
ty proﬁles of the lead excipients were evaluated by comparing
lopes of linear regression lines using Prism software. A p-value
0.05 was considered signiﬁcant. Final decay rates are from the
ower 95% conﬁdence interval based on three formulation experi-
ents. Because this was an initial feasibility experiment, only one
ig. 1. Screening of excipients. Formulations were prepared with LAIV H1N1 (A/Califor
 × 106 log10 TCID50/mL. The formulations were stored at 2–8 ◦C (A) and 25 ◦C (B), and thei
 titer loss greater than 1 log was observed. N = 1 for each formulation tested by TCID50 i
bbreviations:  BSA; bovine serum albumin.4 (2016) 3676–3683
vial of each formulation was  tested in triplicate in each experiment,
limiting the performed statistical analyses.
3. Results
In the ﬁrst formulation stage, excipients were screened for their
ability to improve the stability of LAIV compared to the vaccine
in SPG buffer alone, as assessed by TCID50 (Fig. 1). All formula-
tions were stable at 2–8 ◦C for 6 weeks (Fig. 1A). The addition of
1% arginine (Formulation 9) improved the stability of LAIV com-
pared to SPG buffer alone (Formulation 1) at 25 ◦C. Sorbitol was the
worst-performing excipient at 25 ◦C for both concentrations tested
(Fig. 1B). Arginine and BSA were selected as the best-performing
excipients for further evaluation.
In the second stage, lead formulations were optimized by com-
bining excipients to further improve stability (Fig. 2). In addition,
we tested wider concentration ranges for excipients to ﬁnd the
upper and lower limits of stability improvement. We  also eval-
uated additional excipients: lactalbumin, HPMC, and PVP. As in
the screening phase, arginine (Formulation-09) increased the sta-
bility of LAIV compared to SPG buffer alone (Formulation-01).
Formulations containing arginine alone (Formulation-09 at 1% and
Formulation-12 at 3%), 1% arginine with BSA (Formulation-17 at
0.5% BSA and Formulation-18 at 9% BSA), and 1% arginine with
0.5% gelatin (Formulation-16) showed stability for the length of the
experiment (20 weeks) at 2–8 ◦C (Fig. 2A). Formulations contain-
ing 1% arginine held at 25 ◦C and 33 ◦C showed improved stability
nia/07/2009) in SPG buffer and additional excipients were prepared at a titer of
r titer was measured by TCID50. Formulations were tested for up to 6 weeks or until
n triplicate. Error bars represent the standard deviation of three TCID50 replicates.
J.A. White et al. / Vaccine 34 (2016) 3676–3683 3679
Fig. 2. Formulation optimization. Formulations of LAIV H1N1 (A/California/07/2009) in SPG buffer and additional excipients were prepared at a titer of 2 × 106 log10 TCID50/mL.












witer  loss greater than 1 log was observed. N = 1 for each formulation tested by TC
bbreviations:  SPG, sucrose phosphate glutamate; BSA, bovine serum albumin; HPM
ompared to those using SPG buffer alone. Formulations contain-
ng 3% arginine held at 25 ◦C and 33 ◦C showed an improvement in
tability similar to formulations containing 1% arginine when com-
ared to SPG buffer alone. The formulation containing 1% arginine
nd 0.5% BSA showed the largest stability improvement at 25 ◦C
nd 33 ◦C (Fig. 2B and C). A formulation containing 0.5% gelatin and
% arginine showed stability similar to formulations of 1% arginine
lone at 25 ◦C and 33 ◦C (Fig. 2B and C). HPMC and PVP appeared to
estabilize LAIV and were not included in future formulations.
During the validation stage, LAIV type B (B/Brisbane/60/2008)
as formulated with the lead formulation containing 1% arginine triplicate. Error bars represent the standard deviation of three TCID50 replicates.
droxypropyl methylcellulose; PVP, polyvinylpyrrolidone.
(Formulation-09), and the use of SPG buffer alone (Formulation-01)
was evaluated for comparison. LAIV formulations with 1% arginine
with H1N1 were included to act as a bridge to previous formulation
experiments (inﬂuenza titer of 2 × 106 log10 TCID50/mL). Consistent
with previous experiments, the use of 1% arginine led to statistically
signiﬁcant improvement in stability compared to use of SPG buffer
alone at 2–8 ◦C (p-value <0.0001), 25 ◦C (p-value <0.0001), and 33 ◦C
(p-value of 0.0002 and 0.003, respectively) for both H1N1 and type
B (Fig. 3A–C).
To conﬁrm the formulations selected, we tested a higher con-
centration (1 × 107 log10 TCID50/mL) of LAIV strains (H1N1 and type
3680 J.A. White et al. / Vaccine 34 (2016) 3676–3683
Fig. 3. Formulation validation. Lead formulations were evaluated with an alternate LAIV strain, B/Brisbane/60/2008. Formulations of LAIV H1N1 or type B were prepared in
SPG  buffer or SPG buffer with 1% arginine at a titer of 2 × 106 log10 TCID50/mL. The formulations were stored at 2–8 ◦C (A), 25 ◦C (B), and 33 ◦C (C), and their titer was measured



















1y  TCID50. Formulations were tested for up to 52 weeks or until a titer loss greater
ars  represent the standard deviation of three TCID50 replicates.
) (Fig. 4). The higher titer better mimics what would be present in
 vaccine product. In addition, to avoid using animal-derived raw
aterials, we tested formulations that substituted HSA or rHSA for
SA. Formulations containing 1% arginine (Formulation-09) and
% arginine with 0.5% rHSA (Formulation-20) with both H1N1 and
ype B were stable for the length of the experiment (42.6 weeks
1N1 and 42.2 weeks type B using the lower 95% conﬁdence
nterval) at 2–8 ◦C. H1N1 formulations with 1% arginine improved
tability compared to formulations with SPG buffer alone (p-value
0.0001), but not as much as formulations containing 1% arginine
ith 0.5% rHSA (Formulation-20, p-value <0.0001) at 25 ◦C. How-
ver, at 33 ◦C, H1N1 formulations with 1% arginine or 1% arginine
ith 0.5% rHSA showed similar stability. Type B formulations
ith 1% arginine showed statistically signiﬁcant improvements in
tability compared to formulations with SPG buffer alone at 2–8 ◦C
nd 25 ◦C (p-values <0.0001). Type B formulations with 1% arginine
nd 0.5% rHSA showed slightly improved stability compared to
% arginine alone at 25 ◦C and 33 ◦C. The addition of 0.5% rHSA1 log was  observed. N = 1 for each formulation tested by TCID50 in triplicate. Error
appeared to slightly improve the stability of formulations for
both LAIV H1N1 and type B strains compared to stability with 1%
arginine alone, although these differences were not statistically
signiﬁcant.
By using the decay rate, we  calculated the number of weeks to
reach 1 log10 loss at 2–8 ◦C or 25 ◦C using the lower bound of the 95%
conﬁdence interval (Fig. 4D). Based on three stability experiments,
for H1N1 formulated at a titer of 2 × 106 log10 TCID50/mL with SPG
and 1% arginine, the lower 95% conﬁdence interval for the time to
reach 1 log loss was 32.2 weeks and 2.5 weeks at 2–8 ◦C and 25 ◦C,
respectively.
One experiment was performed with type B formulated at a
titer of 2 × 106 log10 TCID50/mL  with SPG and 1% arginine. The
lower 95% conﬁdence interval for the time to 1 log10 loss at 2–8 ◦C
and 25 ◦C was 50.8 and 3.6 weeks, respectively. Stability testing
with a higher dose of LAIV was performed only once, but the
time to 1 log10 loss for H1N1 at a titer of 1 × 107 log10 TCID50/mL
formulated in SPG with 1% arginine was 36.1 weeks and 2.6 weeks
J.A. White et al. / Vaccine 34 (2016) 3676–3683 3681
Fig. 4. Conﬁrmation of lead formulations containing increased LAIV titer. Formulations of LAIV H1N1 (A/California/07/2009) or type B (B/Brisbane/60/2008) in SPG buffer
and  selected excipients were prepared at a titer of 1 × 107 log10 TCID50/mL. The formulations were stored at at 2–8 ◦C (A), 25 ◦C (B), and 33 ◦C (C), and their titer was measured








tars  represent the standard deviation of three TCID50 replicates. (D) Summary of ti
onﬁdence interval from the average of all three experiments lead formulations we
t 2–8 ◦C and 25 ◦C, respectively. For Type B, the time to 1 log10
oss at the higher concentration was 37.5 weeks and 3.4 weeks.
ormulations with SPG, 1% arginine, and 0.5% rHSA at a titer of
 × 107 log10 TCID50/mL  showed a time to 1 log10 loss of 42.6
eeks and 3.3 weeks for H1N1 and 42.2 weeks and 3.8 weeks for
ype B at 2–8 ◦C and 25 ◦C, respectively. weeks) to 1 log loss for the lead formulations identiﬁed represents the lower 95%
luated. NT = not tested.
We also assessed the effects of agitation and freeze–thaw to
conﬁrm stability. Formulations were prepared with LAIV strains
at titers of 2 × 106 and 1 × 107 log10 TCID50/mL. Agitation and
freeze–thaw were performed to mimic  what a vaccine vial might
encounter during shipment or storage (Fig. 5). The addition of
rHSA to formulations of H1N1 and type B LAIV at titers of
3682 J.A. White et al. / Vaccine 34 (2016) 3676–3683
Fig. 5. Effect of agitation and freeze–thaw stresses on LAIV titer. Formulations of LAIV H1N1 or Type B in SPG buffer and selected excipients were prepared at a titer of 2 × 106
log10 and 1 × 107 log10 TCID50/mL. Agitation was performed by shaking vials horizontally for 24 h at 200 rpm at ambient temperature (20–25 ◦C). Freeze–thaw was performed
































fy  freezing vials at −20 C for 2 h, then thawing at 20–25 C for 1 h for a total of 3 fre
CID50. Error bars represent standard deviation of 3 formulation vials tested in tripl
 × 107 log10 TCID50/mL  improved stability during freezing and agi-
ation compared to formulations with 1% arginine alone and SPG
uffer alone.
. Discussion
This work identiﬁed a stable liquid LAIV formulation for poten-
ial use in monovalent, trivalent, or quadrivalent seasonal inﬂuenza
accines. Through several formulation stages and testing by TCID50,
e identiﬁed a formulation with stability of 42 weeks at 2–8 ◦C for
ype A and type B inﬂuenza LAIV. This formulation consists of SPG
ith 1% arginine and 0.5% rHSA.
Formulation stability of LAIV is inﬂuenced by several factors
e.g., strain, pH buffer, aggregation) [37,38]. SPG is a commonly used
tabilization buffer and is present in several widely used vaccines,
uch as measles, mumps, rubella (MMR)  vaccine and FluMist®
23,39]. Although sorbitol is a well-established osmolyte for sta-
ilizing proteins and preventing aggregation [37,40,41], it did not
tabilize the LAIV strains tested in this study.
Protein-based excipients are commonly used as stabilizers.
ecause of their size and surface activity, they accumulate at the
ir-liquid interface, potentially shielding formulation components
rom surface tension [37,42]. Amino acids use various mecha-
isms to stabilize formulations and are used with a variety of
iomolecules [37,43–45]. l-Arginine and l-glycine, for example, are
ommon excipients for pharmaceutical applications [40,43,46,47].
-Arginine improves stability in a range of applications, including
ntibodies, vaccine antigens, and fusion proteins [43,46,48,49]. l-
rginine may  aid protein refolding, solubilization, the prevention
f aggregation, and the prevention of nonspeciﬁc adsorption [43].
n this study, l-arginine at 1% greatly increased the stability of the
AIV strains tested.
The polymers PVP and HPMC were included because of their
se in mucosal formulations and their potential stabilizing beneﬁts
50]. Because formulations containing these polymers were less
table than formulations with buffer alone, they were removed
rom the ﬁnal formulation experiments. Future work needs tohaw cycles. After the stress tests were completed, the formulations were tested by
evaluate the potential beneﬁts of adding these polymers to the
stable formulation identiﬁed in this work.
In our experiments, only l-arginine with rHSA increased the
stability of the LAIV strains tested. rHSA provided a minor
improvement over formulations containing arginine alone—an
improvement observed most dramatically during freeze–thaw and
agitation experiments with type B. If a vaccine can withstand a
freeze–thaw cycle, freezing can be used to further increase shelf life
by keeping the vaccine frozen at the manufacturing site and then
initiating storage at 2–8 ◦C upon shipment or during short-term
storage at the clinical site. Although BSA showed improved stabil-
ity in the initial stages, we  removed animal-derived products from
our formulations and substituted rHSA because animal-derived
reagents may  cause faith-based concerns or concerns about pos-
sible contamination with endogenous diseases. In addition, HSA
formulations showed increased turbidity over time, which may
have decreased stability. The turbidity could be due to the fatty
acid content in HSA that is not present in rHSA. HSA formulations
could be revisited with a fatty-acid HSA reagent in future experi-
ments.
In conclusion, this paper describes the successful identiﬁcation
of stable liquid LAIV formulations for use in seasonal vaccination
programs. A liquid LAIV formulation allows for a vaccine that is
easier to use, potentially leading to greater acceptance and wider
adoption of seasonal vaccination. The formulations identiﬁed in
this work stabilized LAIV strains H1N1 (A/California/07/2009) and B
(B/Brisbane/60/2008) for approximately one year (42 weeks using
lower 95% conﬁdence interval) at 2–8 ◦C and for up to approx-
imately 4 weeks at 25 ◦C. FluMist® was  developed for vaccine
strains based on use of the A/Ann Arbor/6/60 or B/Ann Arbor/6/66
genetic background. The role of viral genetic differences in formula-
tion stability has not been investigated. Modern seasonal inﬂuenza
vaccines contain three or four strains, so a formulation must suf-
ﬁciently stabilize all included strains. Although we had access to
only two seasonal strains for our studies, the results demonstrate
that both could be stabilized for an entire inﬂuenza season. Ongo-
ing work with a manufacturer is evaluating the addition of 1 log of
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